سعر اوبراستا 5 مجم/100 مل محلول وريدي 2025

Oprasta zoledronic acid 5 mg/100 ml solution for intravenous infusion, one 100 ml vial, by Pharco (Egypt).

• Treatment and prevention of postmenopausal osteoporosis; treatment to increase bone mass in men with osteoporosis; treatment and prevention of glucocorticoid-induced osteoporosis; Paget's disease of bone.DailyMed (U.S. National Library of Medicine)

• Hypocalcemia; creatinine clearance below 35 mL/min or acute renal impairment; known hypersensitivity to zoledronic acid or any component.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Patients receiving Zometa (zoledronic acid 4 mg) should not receive this product; pre-existing hypocalcemia must be corrected and patients supplemented with calcium and vitamin D; renal toxicity risk (hydrate, monitor creatinine clearance); osteonecrosis of the jaw (oral exam before treatment); atypical femoral fractures; severe bone, joint or muscle pain.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• US label: no data on presence of zoledronic acid in human milk or effects on the breastfed infant; weigh benefits of breastfeeding against the mother's need for treatment.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Zoledronic acid: Inhibits osteoclast-mediated bone resorption.